VNDA
VNDA clinical trials: Vanda Pharmaceuticals Inc.
Every trial on ClinicalTrials.gov where Vanda Pharmaceuticals Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 85
- Trials linked
- 82
- As lead sponsor
- 3
- As collaborator
- 2
- Primary completions as lead sponsor, next 90 days
VNDA on the catalyst calendar · VNDA registry changes
- Primary completion Mar 30, 2026ActualPhase 3NCT06836557Open Label Safety Study of Tradipitant in Idiopathic and Diabetic GastroparesisVanda Pharmaceuticals · Idiopathic GastroparesisCompletedVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 4, 2026ActualPhase 3NCT04652882Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)Vanda Pharmaceuticals · Sleep Wake DisordersCompletedVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2028Sponsor estimatePhase 4NCT05648591Safety and Tolerability of Open-Labeled Iloperidone in AdolescentsVanda Pharmaceuticals · SchizophreniaRecruitingVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2028Sponsor estimatePhase 3NCT06830044Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive DisorderVanda Pharmaceuticals · Major Depressive Disorder (MDD)RecruitingVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2028Sponsor estimatePhase 3NCT07362017Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque PsoriasisVanda Pharmaceuticals · Moderate-to-severe Chronic Plaque PsoriasisRecruitingVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 21, 2025ActualPhase 3NCT04028492Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic GastroparesisVanda Pharmaceuticals · Idiopathic GastroparesisCompletedVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 26, 2006ActualPhase 3NCT00254202Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute SchizophreniaVanda Pharmaceuticals · SchizophreniaCompletedVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 1/Phase 2NCT07223632Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual PatientVanda Pharmaceuticals · Charcot Marie Tooth Disease (CMT)Active, not recruitingVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2029Sponsor estimatePhase 3NCT07686081Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative ColitisVanda Pharmaceuticals · Ulcerative Colitis (UC)RecruitingVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 3NCT07221578Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety DisorderVanda Pharmaceuticals · Social Anxiety Disorder (SAD)Active, not recruitingVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2027Sponsor estimatePhase 3NCT06953869Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric InsomniaVanda Pharmaceuticals · Insomnia DisorderRecruitingVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2027Sponsor estimatePhase 3NCT06138613Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion SicknessVanda Pharmaceuticals · Motion SicknessActive, not recruitingVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 3NCT07446439A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist UseVanda Pharmaceuticals · Nausea and VomitingRecruitingVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 1NCT03838926Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic MalignanciesVanda Pharmaceuticals · Relapsed or Refractory Hematologic MalignanciesRecruitingVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 12, 2024ActualPhase 3NCT05366855Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPPVanda Pharmaceuticals · Generalized Pustular PsoriasisTerminatedVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2026Sponsor estimatePhase 2NCT07090161Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled HypertensionVanda Pharmaceuticals · HypertensionRecruitingVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 17, 2023ActualPhase 3NCT05352893Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPPVanda Pharmaceuticals · Generalized Pustular PsoriasisCompletedVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2026Sponsor estimatePhase 2NCT07065773Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe OnychomycosisVanda Pharmaceuticals · Onychomycosis of ToenailActive, not recruitingVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2027Sponsor estimatePhase 3NCT06961968Randomized Withdrawal Study in Patients With SchizophreniaVanda Pharmaceuticals · SchizophreniaRecruitingVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 6, 2025ActualPhase 2NCT06804603A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist UseVanda Pharmaceuticals · ObesityCompletedVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 24, 2024ActualPhase 1NCT06494397Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State ConditionsVanda Pharmaceuticals · SchizophreniaCompletedVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2026Sponsor estimatePhase 2NCT07179055An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry EyeVanda Pharmaceuticals · Dry EyeRecruitingVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 22, 2021ActualPhase 2NCT04622345Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular AllergiesVanda Pharmaceuticals · Allergic ConjunctivitisCompletedVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 15, 2022ActualPhase 2NCT04856930A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis SuppurativaVanda Pharmaceuticals · Hidradenitis SuppurativaCompletedVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 1, 2022ActualPhase 2NCT04856917A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne VulgarisVanda Pharmaceuticals · Acne VulgarisCompletedVNDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 60 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner